Company / Working Capital
Arcus Biosciences, Inc. Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$776.0M
FY2025
5-year range
$647.0M / $1.1B
FY2021-FY2025
Trend
-1.8%
vs FY2024
Sector context
#53 of 213
Health Care
What the data says
Arcus Biosciences, Inc.'s working capital of $776M is higher than 75% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 9 years, ranging from $164M in FY2017 to $1.1B in FY2021.
Based on SEC 10-K filings.
$776M in FY2025 with a 5-year CAGR of +4.8%. Top quartile in the Health Care sector.
Improved from $647M to $776M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -3.9%
- 5-Year CAGR
- +4.8%
- 10-Year CAGR
- -
Sector benchmark
-17.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.8%, indicating consistent growth.
- In FY2025, working capital decreased 1.8% year-over-year.
- Ranks #53 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $776.0M | -1.8% |
| FY2024 | $790.0M | +22.1% |
| FY2023 | $647.0M | -26.0% |
| FY2022 | $874.0M | -20.3% |
| FY2021 | $1.1B | +78.5% |
| FY2020 | $614.1M | +261.3% |
| FY2019 | $170.0M | -29.8% |
| FY2018 | $242.0M | +47.4% |
| FY2017 | $164.1M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026